Recent studies of long-term potentiation (LTP) in the CAl region ofthe hippocampus have demonstrated that nitric oxide (NO) may be involved in some forms ofLTP and have suggested that postsynaptically generated NO is a candidate to act as a retrograde messenger. However, the molecular target(s) of NO in LTP remain to be elucidated. The present study examined whether either of two potential NO targets, a soluble guanylyl cyclase or an ADP-ribosyltansferase (ADPRT; EC 2.4.2.31) plays a role in LTP. The application of membranepermeant analogs of cGMP did not produce any long-lasting alterations in synaptic strength. In addition, application of a cGMP-dependent protein kinase inhibitor did not prevent LTP. We found that the CAl tissue from hippocampus an ADPRT activity that is dramatically stimulated by NO and attenuated by two different inhibitors of mono-ADPRT activity, phyiloquinone and nicotinamide. The extracellular application of these same inhibitors prevented LTP. Postsynaptic injection of nicotinamide failed to attenuate LTP, su Igg n that the critical site of ADPRT activity resides at a nonpostsynaptic locus. These results suggest that ADP-ribosylation plays a role in LTP and are consistent with the idea that an ADPRT may be a target of NO action.
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Long-term potentiation (LTP) in the CA1 region of the hippocampus is an extensively studied form of synaptic plasticity which is initiated by a series ofpostsynaptic events including Ca2+ influx through N-methyl-D-aspartate (NMDA) receptor channels (1) but may be maintained, at least in part, by presynaptic mechanisms (1, 2) . With standard LTP induction protocols at room temperature (3) (4) (5) and with standard (6) (7) (8) or weak (9) (10) (11) induction protocols at warmer temperatures (but see refs. 5 and 12) the diffusible messenger nitric oxide (NO) is required for LTP production, suggesting that NO may mediate the retrograde communication (2, 13, 14) necessary to bring about a presynaptic component of LTP expression. However, the location and identity of the molecular target(s) of NO are still unknown.
The major target of NO in many areas appears to be a guanylyl cyclase (15) (16) (17) (18) . In the hippocampus, high-frequency stimulation can produce rises in cGMP that are blocked by NO synthase inhibitors (10) . In addition, membranepermeant analogs of cGMP have been reported to enhance hippocampal synaptic transmission (19) and reduce the inhibition of LTP produced by NO synthase inhibitors (4) .
ADP-ribosyltransferases (ADPRTs; EC 2.4.2.31) are enzymes that covalently modify their substrate proteins by attaching ADP-ribose moiety(s) from NAD+ or NADP+ to specific residues. Poly-ADPRTs, which attach multiple ADPribose moieties to their substrates, are primarily nuclear enzymes (20) . In contrast, mono-ADPRTs usually attach a single ADP-ribose moiety and possess cytosolic activity (20) . Several endogenous mammalian mono-ADPRTs have been described (21) (22) (23) (24) (25) , but the precise cellular functions of these enzymes remain poorly understood. Early studies suggested that NO-donating compounds can stimulate the ADPribosylation of proteins (26, 27) , including glyceraldehyde-3'-phosphate dehydrogenase (GAPDH). Although the early studies suggested that the modification of GAPDH was mediated by an endogenous ADPRT, subsequent studies have revealed that the modification is mediated by an autocatalytic mechanism (25, (28) (29) (30) (31) . NO may also stimulate the auto-ADPribosylation ofthe poly-ADPRT (32, 33) . In addition, there are numerous reports that NO can stimulate enzyme-mediated ADP-ribosylation of several neuronal proteins (34) (35) (36) (37) (38) . In addition, quite recently Duman et al. (39) have shown that when in vitro assays are performed after LTP induction, less NO-stimulated ADP-ribosylation can be produced in LTPinduced slices than in control slices, suggesting that NOstimulated ADP-ribosylation may occur during LTP induction. To Inhibitors. In hen heterophils, Phyl is reported to be a more potent inhibitor of the mono-ADPRT (IC50 = 1.9 juM) than the poly-ADPRT (IC50 = 520 1uM) (40, 41) . Nic inhibits both the mono-(IC50 = 3400 ,uM) and poly-ADPRT (IC50 = 31 ,uM) (41) . Benzamide is a more potent inhibitor of the poly-ADPRT (IC50 = 3.3 1LM) than the mono-ADPRT (IC5o = 4100 ILM) (41 pg of CA1 homogenate protein. CNBr-activated Sepharose beads were linked to arginine or cysteine by incubation for 3 hr at 4°C with 0.2 M L-arginine or L-cysteine and then washed and resuspended in a Hepes buffer. Twenty microliters of arginine-or cysteine-linked beads was added to a reaction mixture identical to that described above. The mixture was incubated at 37°C for 30 min on a rotator, washed with 500 mM NaCl/10%o (vol/vol) glycerol, and then spun 10 s at 10,000 x g. Individual reactions were conducted in the presence or absence of hippocampal homogenate to examine the dependence of 32p incorporation on exogenous enzyme.
The NO donor 3-morpholinosydnonimine (SIN-1; 500 pM) was also added alone or in the presence of the ADPRT inhibitors Phyl or Nic. 32p incorporation (cpm) was measured with a scintillation counter.
RESULTS
Tests of the Role of cGMP. Previous work indicates that an NO-sensitive guanylyl cyclase activity is present in the hippocampus. To examine the possibility that cGMP may participate in LTP production, phosphodiesterase-resistant membrane-permeant analogs of cGMP (dibutyryl-or 8-bromocGMP; 100 ,uM or 1 mM) were applied extracellularly while the magnitude of the field EPSP was monitored. As has been reported by others (4, 19) , cGMP analogs alone failed to induce any enhancement of synaptic transmission 1101.6% ± 3.8% (mean percent of baseline ± SEM), 30 min after application] (Fig. 1) . Tetanic stimulation delivered to presynaptic afferents in the presence of the cGMP analog and the NMDA receptor antagonist AP5 (50 pM) also failed to produce any synaptic enhancement, although the same tetanic stimulus delivered after the washout ofAP5 and the cGMP analog resulted in LTP ( Fig. 1 A and B) . To assess the involvement of a cGMPdependent protein kinase (cGMP-PK) we applied the general protein kinase inhibitor H-8, which, at low concentrations, is most efficacious in inhibiting cyclic nucleotide-dependent protein kinases (42) . H-8 (10 ,uM) did not affect the magnitude or the time course of the potentiation elicited by tetanic stimulation, suggesting that cGMP-PK activity is not required for LTP production (control, 139.7% ± 13.5%; H-8, 152.9% ± 12.5%; n = 9) ( Fig. 1 C and D) .
NO-Stimulated ADP-Ribosylation. To test if cells in region CA1 of the hippocampus possess NO-stimulated ADPRT activity, we conducted an in vitro assay which examined the ability of CA1 hippocampal tissue to promote the ADPribosylation of amino acid residues. Previous studies (43, 44) have shown that isolated amino acids can serve as exogenous ADP-ribose acceptors for purified ADPRTs. In a similar manner, we linked either arginine or cysteine [ separated from the reaction mixture by a series of centrifugations and also subjected to high-salt washes to remove any ionically bound molecules. In the absence of hippocampal tissue, a small amount of background incorporation of 32p was observed on the beads; this background activity was not affected by the addition of the NO donor SIN-1 at 500 ,uM (Fig. 2) . However, the addition of CA1 homogenate to the ADP-ribosylation reaction mixture significantly stimulated the ADP-ribosylation of both arginine and cysteine (Fig. 2) . This tissue-stimulated ADP-ribosylation was enhanced severalfold by the addition of SIN-1. It is unlikely that the observed ADP-ribosylation is nonenzymatic, since arginine does not undergo this type of reaction (45) and there are no amino groups available for nonenzymatic attachment on cysteine bound to beads. In addition, the NAD glycohydrolase inhibitor isoniazid (20 mM) produced no inhibition of the NO-stimulated ADPribosylation (n = 4; data not shown). In contrast, the mono-ADPRT inhibitors Phyl (100 gM) and Nic (10 mM) significantly attenuated the NO-induced enhancement of the ADPribosylation of arginine and, to a lesser extent, reduced the ADP-ribosylation of cysteine (Fig. 2) . The different sensitivities to the ADPRT inhibitors exhibited by the arginine and cysteine are consistent with the existence of distinct classes of endogenous ADPRTs which preferentially modify arginine or cysteine residues (20, 24) .
It has been reported that NO stimulates the automodification of GAPDH, rather than stimulating the activity of endogenous ADPRT (28) (29) (30) . To test if the NO-stimulated ADP-ribosylation observed in the presence of CA1 tissue could be accounted for by GAPDH present in the hippocampal homogenate, we added purified GAPDH and NO to reaction mixtures in the absence of CA1 tissue. The addition of GAPDH and NO failed to promote the ADP-ribosylation of either arginine or cysteine (Fig. 2) . Thus, these data indicate that under these particular experimental conditions NO does not stimulate GAPDH-mediated ADP-ribosylation of exogenous amino acids.
Extracellular Application of ADPRT Inhibitors. To test whether the activity of an ADPRT participates in LTP production we utilized the same ADPRT inhibitors that attenuated the endogenous hippocampal ADPRT activity (Fig. 2) . In each experiment, two afferent pathways in the same slice were utilized to examine both control and inhibitor-treated potentiation. Phyl was also a very effective blocker of LTP, at a concentration (100 gM) well below the IC50 for inhibition of the poly-ADPRT reported in other tissue [control potentiation, 161.0% ± 18.4%; Phyl, 111.0o ± 6.4% (mean percent of baseline ± SEM)] (Fig. 3 A and D) . The ADPRT inhibitor Nic also blocked LTP, in a dose-dependent (Fig. 3 B and D 6.0%o; 1 mM Nic (n = 9), 109.1% ± 8.7%; 200 ,uM Nic (n = 8), 143.1% ± 7.3%]. The observed dose-response profile fits with the interpretation that Nic is working by inhibiting a mono-rather than a poly-ADPRT. Nic (1-5 mM) also blocked LTP when experiments were conducted at 30'C rather than room temperature [91.7% ± 11.7% (n = 6)]. To directly assess the potential involvement of a poly-ADPRT we used the poly-ADPRT inhibitor benzamide at 100 jiM (40, 41) . In contrast to the block of LTP observed with Phyl and Nic, benzamide did not prevent tetanus-induced enhancement of synaptic transmission (control, 161.0%, ± 9.1%; benzamide, 167.1% ± 18.6%) (Fig. 3 C and D) . Taken together, these data suggest that mono-rather than poly-ADPRT activity is necessary for the induction of LTP.
A blockade of LTP was observed with two different ADPRT inhibitors (Phyl and Nic) with distinct chemical structures, arguing against a nonspecific pharmacological effect being responsible for the prevention of LTP. As illustrated in Fig. 4A , neither of the ADPRT inhibitors that were effective in blocking LTP had any significant effect on basal excitatory synaptic transmission. In addition, neither inhibitor had any significant effect on either the inhibitory postsynaptic potential (IPSP) recorded in pyramidal neurons (mean of control IPSP ± SEM: Phyl, 95.7% + 1.3%, n = 3; Nic, 91.8% ± 5.4%, n = 4) (Fig. 4B) or on the NMDAmediated component of the EPSC measured with whole-cell recording (mean of control current ± SEM: Phyl, 101.3% + 9.4; Nic, 96.8% ± 8.7). Fig. 4 also illustrates that the NO synthase inhibitor L-methylarginine, previously reported to block LTP, has no effect on the amplitude of the NMDA current. In addition, L-nitroarginine (10-100 &M) does not affect the pharmacologically isolated NMDA-receptormediated extracellular field potential (data not shown). The inability of Phyl and Nic to alter basal excitatory, inhibitory, and NMDA-mediated synaptic transmission is consistent Proc. Natl. Acad. Sci. USA 91 (1994) 11961 with the interpretation that these drugs block LTP by interfering with the ADPRT activity.
Postsynaptic Injection of ADPRT Inhibitor. To ascertain whether postsynaptic ADPRT activity is important for LTP, Nic was injected directly into an individual postsynaptic CA1 pyramidal neuron through the intracellular recording microelectrode (Fig. 5) (34, 35) . The electrophysiological data provide evidence that ADPRT activity may be an important step in LTP production. Two chemically distinct ADPRT inhibitors prevented LTP, without affecting basal excitatory or inhibitory synaptic transmission or affecting the magnitude of the NMDA-mediated whole-cell currents. Naturally, our interpretation ofthese data relies on the specificity of the inhibitors we have used; in future experiments it will be necessary to examine directly whether ADP-ribosylation is involved in LTP.
It is interesting to speculate on potential mechanisms that involve ADPRT activity in the presynaptic terminal. Common targets for mono-ADP-ribosylation include GTP-binding proteins (20, 24, 34, 47) and the growth-associated protein GAP-43/B-50 (48) . Recent reports indicate that NO can stimulate neurotransmitter release fom isolated hippocampal nerve terminals (45, 49) . Since both G proteins and GAP-43 may modulate exocytosis (50, 51) , the regulation of these protein(s) by NO-stimulated ADP-ribosylation could potentially lead to increases in neurotransmitter release that may function as a mechanism of LTP expression.
